2552 Share Price Performance
HK$0
-4.21 (-100.00%)
Price HK$0
Fair ValueHK$5.52
Share Pricen/a
New Narrative • Sep 08
Hua Medicine (Shanghai) Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
2552 Community Narratives
AN
Fair Value
·Fair Value HK$5.52 56.4% undervalued intrinsic discount
Glucose Homeostasis Platform Will Broaden Metabolic Indications And Support Long Runway
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Hua Medicine (Shanghai)
56.4% undervalued intrinsic discount
New
Glucose Homeostasis Platform Will Broaden Metabolic Indications And Support Long Runway
View narrativeAN
Published 8 Sep
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Glucose Homeostasis Platform Will Broaden Metabolic Indications And Support Long Runway
Fair Value: HK$5.52 56.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Hua Medicine (Shanghai) Ltd. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.11
- 60.64%
- -16.47%
- 31.6%
About 2552
- Founded
- 2011
- Employees
- 424
- CEO
- WebsiteView website
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
